Diabetes & Endocrinology – Page 20

Long-Term Progression and Risk Factors of Diabetic Retinopathy in Type 2 Diabetes: Insights from the Skaraborg Cohort in Sweden

By MedXY 10/31/2025

This cohort study tracks diabetic retinopathy incidence over 24 years in type 2 diabetes patients, highlighting the impact of glycemic control and hypertension on disease progression.

Diabetes & Endocrinology Internal Medicine news

Comparative Efficacy and Safety of Tirzepatide, Semaglutide, and Liraglutide for Obesity Management: A Critical Review of Recent Cochrane Evidence

By MedXY 10/31/2025

This article critically compares the efficacy, safety, and long-term outcomes of tirzepatide, semaglutide, and liraglutide for the treatment of obesity based on recent Cochrane systematic reviews, highlighting differences in weight loss, adverse events, cardiovascular outcomes, and evidence certainty.

Diabetes & Endocrinology news

Enhanced Glycemic Control in Type 1 Diabetes Through Systematic Intensive Therapy and Continuous Glucose Monitoring

By MedXY 10/29/2025

Systematic intensive therapy combined with continuous glucose monitoring significantly improves glycemic control in adults with type 1 diabetes not meeting targets, without increasing adverse events.

Diabetes & Endocrinology news Ophthalmology

Glucagon-Like Peptide-1 Receptor Agonists and Ocular Risks: A Comprehensive Review of Neovascular AMD, Diabetic Retinopathy, and Ischemic Optic Neuropathy in Diabetes

By MedXY 10/29/2025

GLP-1 receptor agonists used in diabetes show a twofold increased risk of neovascular AMD, a modest risk elevation for diabetic retinopathy, and a small but significant increased risk for nonarteritic anterior ischemic optic neuropathy, warranting careful ophthalmic monitoring.

Diabetes & Endocrinology Internal Medicine news

Handgrip Strength as a Predictor of Preclinical Obesity Progression and Mortality: Insights from the UK Biobank Multistate Model Analysis

By MedXY 10/29/2025

This study reveals that higher handgrip strength is significantly associated with reduced risks of preclinical obesity progression and mortality, highlighting the importance of muscle strength in managing early obesity-related health risks.

Diabetes & Endocrinology news Public Health

Disentangling Clinical and Preclinical Obesity: Their Distinct Impacts on All-Cause Mortality Risk in the UK Biobank Study

By MedXY 10/29/2025

New evidence from the UK Biobank reveals that clinical obesity, defined by obesity-related dysfunctions, significantly elevates all-cause mortality risk. Early detection and intervention are key to reducing mortality associated with both preclinical and clinical obesity.

Diabetes & Endocrinology news Public Health

Sustained Impact of Lifestyle and Metformin Interventions on Type 2 Diabetes Prevention: Insights from 21 Years of the US DPP Trial

By MedXY 10/29/2025

Over 21 years, intensive lifestyle changes and metformin significantly reduced type 2 diabetes incidence in at-risk adults, with variable effects based on individual baseline risk factors, highlighting opportunities for precision prevention.

AI Clinical Updates Diabetes & Endocrinology news

Evaluating AI-Led vs Human-Led Lifestyle Interventions in Prediabetes: Evidence from a Randomized Clinical Trial of the Diabetes Prevention Program

By MedXY 10/29/2025

This review examines the first phase 3 randomized trial demonstrating that an AI-powered Diabetes Prevention Program lifestyle intervention is noninferior to human coaching in improving weight loss, HbA1c, and physical activity among adults with prediabetes and overweight or obesity.

Diabetes & Endocrinology Gastroenterology news

Plant-Based Foods and Their Impact on Metabolic Health and Liver Function in Adults with MASLD and Comorbidities: A Systematic Review

By MedXY 10/28/2025

This systematic review evaluates the effects of specific plant-based foods on metabolic and hepatic outcomes in adults with MASLD and related comorbidities. Findings reveal selective benefits of plant-based dietary components on liver health, glycemic control, and lipid profiles, underscoring potential dietary strategies for MASLD management.

Diabetes & Endocrinology Gastroenterology news

Time-Restricted Eating as a Promising Approach for Metabolic Dysfunction-Associated Steatotic Liver Disease: Evidence from a Randomized Controlled Trial

By MedXY 10/28/2025

A 16-week RCT demonstrates that time-restricted eating significantly reduces hepatic steatosis in MASLD, offering comparable metabolic benefits to calorie restriction without adverse events.

Diabetes & Endocrinology General Surgery news

Bariatric Surgery Significantly Reduces Risk of Developing Major Obesity-Related Comorbidities: Insights from a Large Veterans Cohort

By MedXY 10/27/2025

A large retrospective cohort study reveals bariatric surgery markedly lowers the incidence of key metabolic comorbidities compared to weight management alone in obese veterans, supporting its role in durable obesity-related risk reduction.

Diabetes & Endocrinology news Pediatrics

Automated Insulin Delivery Systems: Transforming Glucose Management in Youth with Type 1 Diabetes

By MedXY 10/27/2025

Automated insulin delivery (AID) systems significantly improve glucose control and reduce hypoglycemia and hyperglycemia in children and adolescents with type 1 diabetes, without increasing adverse events.

Diabetes & Endocrinology news Ophthalmology

Glucagon-Like Peptide-1 Receptor Agonists May Lower the Risk of Nonexudative Age-Related Macular Degeneration in Obese Non-Diabetic Adults

By MedXY 10/26/2025

A large retrospective cohort study reveals that GLP-1 receptor agonists significantly reduce the risk of developing nonexudative age-related macular degeneration in obese individuals without diabetes, with no effect on progression to exudative AMD.

Diabetes & Endocrinology Oncology

Targeting Tumor Hypoxia Pathways: Belzutifan’s Promise in Advanced Paraganglioma and Pheochromocytoma Treatment

By MedXY 10/25/2025

This article reviews a phase 2 trial of belzutifan, a HIF-2α inhibitor, demonstrating durable antitumor activity and manageable safety in advanced pheochromocytoma and paraganglioma, highlighting its potential as a targeted therapy.

Diabetes & Endocrinology news Ophthalmology

Impact of Multifactorial Interventions on Retinopathy in Type 2 Diabetes: Insights from the J-DOIT3 Trial

By MedXY 10/24/2025

This analysis highlights how intensive multifactorial management and glycemic control influence diabetic retinopathy onset, emphasizing the risks associated with hypoglycemia despite good glycemic control.

Diabetes & Endocrinology OB/GYN & Women's Health

Closed-Loop Insulin Delivery in Type 1 Diabetes During Pregnancy: Insights from the CIRCUIT Randomized Clinical Trial and Contemporary Evidence

By MedXY 10/24/2025

The CIRCUIT trial demonstrates that closed-loop insulin delivery significantly improves glycemic control during pregnancy in type 1 diabetes, increasing time in pregnancy-specific glucose range and reducing hypoglycemia risks relative to standard care.

Diabetes & Endocrinology OB/GYN & Women's Health Specialties

Navigating the Frontiers of Premature Ovarian Insufficiency Research: Insights from the Top 100 Influential Articles

By MedXY 10/22/2025

A comprehensive bibliometric analysis of the 100 most-cited articles in premature ovarian insufficiency reveals key research trends, leading contributors, and emerging scientific directions in genetics, cardiovascular disease, and immunology.

Diabetes & Endocrinology HIV/AIDS Internal Medicine Specialties

Nucleoside Reverse Transcriptase Inhibitors: A Novel Therapeutic Avenue Against Inflammaging and Age-Related Diseases

By MedXY 10/22/2025

NRTIs, traditionally used in HIV and HBV treatment, demonstrate promising anti-inflammatory effects that may reduce the incidence of age-related diseases by inhibiting inflammaging processes associated with endogenous retroelements.

Diabetes & Endocrinology Psychiatry Specialties

Semaglutide for Metabolic Health in Schizophrenia: Insights from the HISTORI RCT

By MedXY 10/22/2025

The HISTORI trial demonstrates that semaglutide significantly improves glycemic control, reduces weight, and enhances physical quality of life in schizophrenia patients treated with second-generation antipsychotics, without worsening psychiatric symptoms.

Diabetes & Endocrinology news Public Health

Leveraging the Planetary Health Diet to Reduce Type 2 Diabetes Risk and Environmental Impact: Insights from the EPIC-Norfolk Study

By MedXY 10/20/2025

Higher adherence to the planetary health diet is linked with a 32% reduced risk of type 2 diabetes and significantly lower greenhouse gas emissions, supporting its role in preventing diabetes and promoting sustainability.